SOM230, an IGF-I action inhibitor, evaluated for breast cancer chemoprevention in high-risk women
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Abstract
A proof-of-principle trial investigates SOM230's ability to reduce cell proliferation and increase apoptosis in the mammary glands of high-risk women, mirroring rat study results.